ClinicalTrials.gg
RecruitingNCT04707300HTLP-ONCOUpdated Aug 12, 2026

Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO)

A Phase 1/2 interventional study of Human T Lymphoid Progenitor (HTLP) injection in Hematologic Malignancy, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 5 sites in France. Open to participants aged 18 Years to 66 Years. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2022; still recruiting 4 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 66 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Hematologic Neoplasms by Assistance Publique - Hôpitaux de Paris — 6 open to participants now, 6 under way, 1 of them phase 3. Hematologic Neoplasms · Assistance Publique - Hôpitaux de Paris.

Started
2022
with 1 other
Phase 1/2
4 of 16
2 open now
Registered
10th of 16
by date

Among the 16 studies in Hematologic Neoplasms by Assistance Publique - Hôpitaux de Paris, this one is one of 2 that started in 2022, is one of 4 in phase 1/2, and was the 10th registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

6 of the 16 studies in Hematologic Neoplasms by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years to 66 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Hematologic Neoplasms by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

This is an open-labelled and non-controlled Phase I/II clinical trial, evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after umbilical cord blood (UCB) transplantation in adult patients with hematologic malignancies. The dose limiting toxicity of HTLP injection will be evaluated using a model-based design.

Read the detailed description

Allogeneic bone marrow transplantation (AlloSCT) is the treatment of choice for high- risk acute myeloid leukemias in complete first remission after induction therapy and other high-risk hematological malignancies. Umbilical cord blood grafts are frequently used for patients lacking an HLA- matched family donor (Matched-sibling donor, MSD) as well as in the absence of an appropriate unrelated donor (10/10 MUD). As any HSCT, UCB transplantations are associated with the risk of acute and chronic GVHD, post- transplant immunodeficiency with increased risk of infections as well as relapse. Especially the risk of infection and therefore non- relapse mortality (NRM) or transplant- related mortality (TRM) is significantly higher in UCB transplantations as compared to MSD or 10/10 MUD transplantations. All of these risks have been linked to a significant delay in immune reconstitution including various immune cell populations like CD4 and CD8 T cells, Treg, NK, iNKT, pDC and others.

The investigators therefore make the hypothesis that if T-cell-mediated immunity was rapidly generated after a partially HLA-compatible UCB transplantation will reduce the risk of infection and to prevent relapse without increasing the risk of GVHD.

03

Conditions studied

  • Hematologic Malignancy

Keywords

  • acute myeloid leukemia
  • minimal residual disease
  • hematologic malignancies
  • human T Lymphoid Progenitor
  • umbilical cord blood transplantation
04

Who can participate

Ages eligible
18 Years to 66 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (≥ 18 years old and \<66 years old) at the time of inclusion and eligible for an stem cells transplantation and fit to receive the specified conditioning regimen
  • Patients with hematologic
  • Absence of a matched - related sibling donor (MSD) or a matched unrelated donor (MUD) 10/10
  • Presence of two UCB units with the following criteria*: HLA- matched 4/8, 5/8, 6/8, 7/8 or 8/8 for HLA- A, -B, -C and DRB1 loci

AND

  • Presence of at least one UCB unit with the following criteria*: ≥ 3 x 10e7 TNC/kg or ≥ 1.5 10e5 CD34+/kg pre- freezing

* For the UCB taken into HTLP culture, the CD34+ content does not need to meet the above cellularity criteria, as expansion during HTLP culture has been proven to ensure the appropriate number of CD7+ needed for each dose.

The non- cultured UCB will be chosen to have a higher CD34+ cell content in order to enable long- term hematopoietic engraftment

  • Absence of Donor Specific Antibodies (DSA) with a MFI > 5000
  • Patient affiliated to social security
  • Written, of the patient

Exclusion criteria

Exclusion Criteria:

  • Any of the standard to transplant
  • \<50%
  • Abnormal biochemistry results (/AST>10xULN, total >2.5xULN, creatinin clearance \<60ml/min)
  • Inability to understand and provide
  • Concomitant infectious disease: HTLV-I, -I or HIV-II
  • Pregnancy or breastfeeding for women of
  • Patients with progressive hematologic
  • Previous participation within one month before inclusion in another protocol in which drugs may influence immune reconstitution of bone marrow transplantation
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Human T Lymphoid Progenitor (HTLP) injection

    HTLP cellular product obtained after 7 days of culture of immune-selected CB

    Drug: Human T Lymphoid Progenitor (HTLP) injection

Interventions

  • DrugHuman T Lymphoid Progenitor (HTLP) injection

    The HTLP cell suspension will be injected intravenously at the time of UCB HSCT on D0

06

What researchers measure

Primary outcomes

  1. Cumulative incidence of grade III-IV graft-versus-host disease (GvHD)

    according to Glucksberg grading system, to define toxicity

    Time frame: Within 100 Days following HSCT

  2. CD4 + T cells analysis

    Efficacy defined by the presence of \>50/μl CD4+ CD3+ TCRαβ+ T cells at 2 consecutive measures \< within 4 months post HSCT.

    Time frame: Within 100 days following HSCT

Secondary outcomes

  1. Time to hematologic engraftment

    ANC \> 0.5G/L and platelets \> 20G/L on 3 consecutive days

    Time frame: Up to 24 months post-transplantation

  2. Last transfusion of platelets and red blood cell

    Time frame: During the follow-up

  3. Absolute numbers of neutrophils

    Time frame: Month 1, 2, 3, 6 and 12 post -transplantation

  4. Time course of T cell immune reconstitution

    by immunophenotyping (flow cytometry analysis) - with a focus on time needed to exceed a count of 100 naive CD4+ and \>100 total CD8+ cells per μL

    Time frame: Month 1, 2, 3, 6 and 12 post -transplantation

  5. Immune phenotype (flow-cytometry analysis) of the different TCRαβ+ cell subpopulations

    TCD4 naive/memory population (CD31+CD45RA+/CD4+, CD45RO/CD4+; CD31+CD4+); TCD8 naive/memory population (CD45RA+CCR7+/CD8+, CD45RA-CCR7+/ CD8+, CD45RA- CCR7+/ CD8+, CD45RA-CCR7-/CD8+) , CD8 effector memory RA+ (TEMRA) (CD45RA+CCR7- /CD8+ ); Regulatory T cells (CD4+CD25+CD127lowCD25+). • Analysis of CD3, CD4, CD8 numbers will be performed if total lymphocytes ≥ 500/μL and analysis of T cell subpopulations if CD3+ cells ≥ 1000/μL

    Time frame: Month 1, 2, 3, 6 and 12 post -transplantation

  6. B-cell reconstitution

    (B CD19 naive/memory population (CD27-IgD+/CD19+, CD27+IgD+/CD19+, CD27+IgD-/CD19 and Ig levels) at 1, 2, 3, 6 and 12 months post HSCT with focus on time needed for cessation of intravenously IgG replacement therapy

    Time frame: Month 1, 2, 3, 6 and 12 post -transplantation

  7. Reconstitution of the NK cell

    compartment (CD16+CD56+)

    Time frame: Month 1, 2, 3, 6 and 12 post -transplantation

  8. Assessment of engraftment of each UCB unit over time by hematological monitoring and chimerism analysis

    at 1, 2, 3, 6 and 12 months following HSCT and between M1 and M2 post-transplantation if necessary according to the result of the chimerism at M1 on neutrophils, T, B, NK, pDC and macrophages. • The chimerism is studied on whole blood and on mononuclear cells (i.e. cells reconditioning after Ficoll) until the total number of lymphocyte is ≥ 100/μL. When lymphocyte count is ≥ 100/μL, the chimerism will be analysed on immunoselected cell populations (CD15+/CD3+/NK, CD19+)

    Time frame: at 1, 2, 3, 6 and 12 months following HSCT.

  9. Graft failure/rejection rate

    detected by hematological monitoring of each UCB unit

    Time frame: at 3 months following HSCT

  10. Cumulative incidence of infections

    Time frame: at 3, 6 and 12 months post- transplantation

  11. Cumulative incidence of acute and chronic episodes of GVHD and their grade according to Glucksberg GvHD staging.

    Time frame: at 3, 6, 12 and 24 months post-transplantation

  12. Relapse rate

    Time frame: 2 years

  13. Overall survival

    Time frame: 2 years

  14. Disease-free survival

    Time frame: 2 years

  15. Progression-free survival

    Time frame: 2 years

07

Study locations

4 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Jun 2027, 64 months after the start.

Of 64 phase 1/2 interventional studies under Hematologic Neoplasms, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 127. This study's planned 64 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2020
First posted
Jan 13, 2021
StartActual
Feb 16, 2022
Primary completionEst.
Jun 2027
CompletionEst.
Feb 2029
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04707300
Collaborators
URC-CIC Paris Descartes Necker Cochin
Responsible party
Sponsor
First posted
Jan 13, 2021
Start date
Feb 16, 2022
Primary completion
Jun 2027 (estimated)
Completion
Feb 2029 (estimated)
Last update
Aug 12, 2026

Study contacts

Olivier HERMINE, PhD & MD
Contact
olivier.hermine@aphp.fr
+33 144495282
Nelly Briand, PhD
Contact
nelly.briand@aphp.fr
01 44 38 18 62 ext. +33
Olivier HERMINE, PhD & MD
principal investigator · Assistance Publique - Hôpitaux de Paris
Elisa MAGRIN, MD
study director · Département de Biothérapie : Hôpital Necker Enfants malades

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion